A prosztatarák epidemiológiája

Cikk címe: A prosztatarák epidemiológiája

Szerzők: Dr. Biró Krisztina

Intézmények: Országos Onkológiai Intézet

Évfolyam: XII. évfolyam

Lapszám: 2013. /

Oldal: 48-54

Terjedelem: 7

Rovat:

Alrovat:

Absztrakt:

A prosztatarák világszerte a második leggyakoribb daganatos betegség. 2008-ban világszerte megközelítőleg 900 000 új esetet diagnosztizáltak, és 280 000-en haltak meg ebben a betegségben. Incidenciája és mortalitása akár 50-szeres különbségeket is mutathat a világ különböző országai között. Ezeket az adatokat persze óvatosan érdemes kezelni, hiszen a több országban bevezetett PSA szűrőprogram megnövelte a tünetmentes férfiakon PSA emelkedés miatt elvégzett biopsziák számát, ami viszont hirtelen jelentős incidencia emelkedéssel járt. Azokban az országokban, ahol nincs szűrőprogram, tipikusan alacsonyabb az incidencia, mint azokban, ahol van. Az alábbi összefoglalóban a prosztata daganatok 99%-át adó prosztata adenocarcinoma epidemiológiájáról és etiológiájáról a jelenleg rendelkezésre álló ismereteket foglalom össze.

Abstract:

Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 new cases and 258,000 deaths in 2008. Incidence and death rates of prostate cancer show large variability – even a 50- fold difference – across different countries worldwide. However, interpretation of these data is complicated by the fact, that in countries, where PSA screening programs were introduced, the incidence of prostate cancer has been dramatically increased due to the increased frequency of prostate biopsies performed in asymptomatic men, who have an elevated prostate specific antigen (PSA) level. Countries do not utilize PSA testing, typically have a much lower incidence rate of prostate cancer, compared to those who do. This review will focus on the etiology and epidemiology of adenocarconoma, the most common histologic type of prostate cancer, which comprises over 99 percent of the cases.

Szerző Intézmény
Dr. Biró Krisztina Országos Onkológiai Intézet

[1] Globocan 2008. v1.2 Cancer incidence and mortality worldwide.
[2] Jemal, A. et al: CA Cancer, J Clin 2006;56:106-130.)
[3] Ottó Sz, Kásler M: A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása, Magyar Onkológia (49. évfolyam 2. szám 2005)
[4] Andriole GL, Crawford ED, Grubb III RL, et al: PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial, N Engl J Med 2009;360:1310–9.
[5] SEER Cancer Statistics Review, 1973-1999 http://seer.cancer.gov/csr/1973_1999/ (Accessed on February 25, 2011).
[6] Hankey BF, Feuer EJ, Clegg LX, et al: Cancer surveillance series: interpreting trends in prostate cancer–part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates, J Natl Cancer Inst 1999; 91:1017.
[7] Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer, Cancer Control 2006; 13:158.
[8] Parker PM, Rice KR, Sterbis JR, et al: Prostate cancer in men less than the age of 50: a comparison of race and outcomes, Urology 2011; 78:110.
[9] Hoffman RM, Gilliland FD, Eley JW, et al: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study, J Natl Cancer Inst 2001; 93:388. [10] Bruner DW, Moore D, Parlanti A, et al: Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis, Int J Cancer 2003; 107:797.
[11] Steinberg GD, Carter BS, Beaty TH, et al: Family history and the risk of prostate cancer, Prostate 1990; 17:337.
[12] Lichtenstein P, Holm NV, Verkasalo PK, et al: Environ mental and heritable factors in the causation of cancer– analyses of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med 2000; 343:78.
[13] Zheng SL, Sun J, Wiklund F, et al: Cumulative association of five genetic variants with prostate cancer, N Engl J Med 2008; 358:910.
[14] Edwards SM, Evans DG, Hope Q, et al: Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis, Br J Cancer 2010; 103:918.
[15] Narod SA, Neuhausen S, Vichodez G, et a: Rapid progression of prostate cancer in men with a BRCA2 mutation,Br J Cancer 2008; 99:371.
[16] www.asco.org
[17] Endogenous Hormones and Prostate Cancer Colla bo ra – tive Group, Roddam AW, Allen NE, et al: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies, J Natl Cancer Inst 2008; 100:170.
[18] Roddam AW, Allen NE, Appleby P, et al: Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies, Ann Intern Med 2008; 149:461.
[19] MacInnis RJ, English DR: Body size and composition and prostate cancer risk: systematic review and meta-regression analysis, Cancer Causes Control 2006; 17:989.
[20] Su LJ, Arab L, Steck SE, et al: Obesity and prostate cancer aggressiveness among African and Caucasian
Americans in a population-based study. Cancer Epidemiol Biomarkers Prev 2011; 20:844.
[21] Giovannucci EL, Liu Y, Leitzmann MF, et al: A prospective study of physical activity and incident and fatal prostate cancer, Arch Intern Med 2005; 165:1005.
[22] Platz EA, Leitzmann MF, Michaud DS, et al: Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study, Cancer Res 2003; 63:8542.
[23] Schulman CC, Ekane S, Zlotta AR: Nutrition and prostate cancer: evidence or suspicion? Urology 2001; 58:318.
[24] Chan JM, Gann PH, Giovannucci EL: Role of diet in prostate cancer development and progression, J Clin Oncol 2005; 23:8152.
[25] Giovannucci E, Rimm EB, Colditz GA, et al: A prospective study of dietary fat and risk of prostate cancer, J Natl Cancer Inst 1993; 85:1571.
[26] Sinha R, Park Y, Graubard BI, et al: Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States, Am J Epidemiol 2009; 170:1165.
[27] Cohen JH, Kristal AR, Stanford JL: Fruit and vegetable intakes and prostate cancer risk, J Natl Cancer Inst 2000; 92:61.
[28] Kirsh VA, Peters U, Mayne ST, et al: Prospective study of fruit and vegetable intake and risk of prostate cancer, J Natl Cancer Inst 2007; 99:1200. [29] Bagnardi V, Blangiardo M, La Vecchia C, Corrao G: A meta-analysis of alcohol drinking and cancer risk, Br J Cancer 2001; 85:1700.
[30] EA Klein, IM Thompson, CM Tangen, et al: Vitamin E and the Risk of Prostate Cancer: Results of The Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA 2011; 306(14) 1549-1556.
[31] Lawson KA, Wright ME, Subar A, et al: Multivitamin use and risk of prostate cancer in the National Institutes of